The DOI matches its Crossref record.
Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma.
Abstract
3003 Background: Inhibition of the MAPK pathway with dabrafenib (D) and trametinib (T) is efficacious in BRAF-mutant melanoma. MEK inhibitors have also shown activity in BRAF WT melanoma, particularly in NRAS-mutant tumors. However, most patients (pts) develop resistance to D and T. MEDI4736 (M), a human IgG1 mAb that blocks PD-L1 binding to PD-1 and CD80 with high affinity and selectivity, has shown clinical activity with durable responses and an acceptable safety profile in multiple tumor types. Combined therapy with these agents may lead to enhanced durable tumor responses. Methods: A phase I, multicenter, open-label study (NCT02027961) evaluating the safety and efficacy of M at 3 or 10 mg/kg IV every 2 weeks (q2w) in combination with D 150 mg twice daily + T 2 mg daily, or T alone in pts with stage IIIc/IV melanoma. Pts enroll by BRAF status into dose escalation cohorts (3+3 design), followed by dose expansion: BRAF mutant in Cohort A (M+D+T); BRAF WT in Cohort B (M+T) or Cohort C (sequential T→M). Prior BRAF/MEK inhibitors were prohibited; prior immunotherapy was allowed, including anti-PD-1/anti-PD-L1 therapy. Results: As of December 5, 2014, 50 pts were treated. DLTs were observed in 1 pt in Cohort A1 (reversible grade [G] 3 thrombocytopenia) and 1 pt in Cohort B (reversible G3 choroidal effusion). No MTD was identified; M 10 mg/kg q2w was selected for expansion in all cohorts. The most frequent drug-related adverse events (AEs) by cohort were: pyrexia (63%) and fatigue (54%) (Cohort A); diarrhea (30%) and rash (25%) (Cohort B); and vomiting (67%) (Cohort C). 2 pts discontinued due to drug-related AEs (DLTs above). Clinical activity to date is shown below. Most responses are ongoing (range of duration: 0.1+ - 32+ wk). Conclusions: M can be combined with T ± D at full doses with a manageable safety profile, and evidence of clinical activity in BRAF-mutant and WT melanoma. Clinical trial information: NCT02027961. Cohort n Any AE (%) Related AE (%) Related G ≥ 3 AE (%) CR/PR (n/n)a SD (n/n)a A1 (3 mg/kg M + D + T) 6 100 100 17 6/6 0/6 A2 (10 mg/kg M + D + T) 18 94 94 39 10/15 5/15 B (10 mg/kg M + T) 20 90 85 40 3/14 6/14 C (sequential T + 10 mg/kg M) 6 100 100 17 3/6 1/6 aIncludes pts with ≥ 1 follow up scan or discontinuation due to PD or death prior to first scan (confirmed and unconfirmed CR/PR).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
Naidoo, J., Page, D. B., Li, B. T., Connell, L. C., Schindler, K., Lacouture, M. E., Postow, M. A., & Wolchok, J. D. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv383 · Cited by 1,470
Self-citationCombination cancer immunotherapy and new immunomodulatory targets
Mahoney, K. M., Rennert, P. D., & Freeman, G. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4591 · Cited by 1,294
Targeted agents and immunotherapies: optimizing outcomes in melanoma
Luke, J. J., Flaherty, K. T., Ribas, A., & Long, G. V. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.43 · Cited by 1,254
Self-citationGutzmer, R., Stroyakovskiy, D., Gogas, H., Robert, C., Lewis, K., Protsenko, S., Pereira, R. P., Eigentler, T., Rutkowski, P., Demidov, L., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30934-x · Cited by 663
Self-citationFares, C. M., Van Allen, E. M., Drake, C. G., Allison, J. P., & Hu-Lieskovan, S. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_240837 · Cited by 653
Metadata
- Authors
- Ribas, A., Butler, M., Lutzky, J., Lawrence, D. P., Robert, C., Miller, W., Linette, G. P., Ascierto, P. A., Kuzel, T., Algazi, A. P., Postow, M. A., Nathan, P. D., Curti, B. D., Robbins, P. B., Li, X., Blake-Haskins, J. A., & Gordon, M. S.
- Venue
- Journal of Clinical Oncology
- Published
- 2015-05-20
- Volume
- 33
- Issue
- 15_suppl
- Pages
- 3003-3003
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2513415897
- Cited by
- 158
- References
- 0
- Type
- conference abstract
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma. https://app.cochat.ai/papers/10.1200/jco.2015.33.15_suppl.3003
- The paper
- Ribas, A., Butler, M., Lutzky, J., Lawrence, D. P., Robert, C., Miller, W., Linette, G. P., Ascierto, P. A., Kuzel, T., Algazi, A. P., Postow, M. A., Nathan, P. D., Curti, B. D., Robbins, P. B., Li, X., Blake-Haskins, J. A., & Gordon, M. S. (2015). Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2015.33.15_suppl.3003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.